Rational 'Co-Design' of Targeted Anticancer Therapeutics

Rational 'Co-Design' of Targeted Anticancer Therapeutics: Integrating Immuno Oncology, Biomaterials, and Translational Systems presents a unified, system level framework that designs molecules, carriers, and delivery pathways concurrently for clinically translatable cancer therapies. The book details how electronic structure, molecular recognition, biomaterial compatibility, immune microenvironment dynamics, and ADMET/AI models integrate into end to end decision frameworks—from in silico prediction to experimental validation and regulatory readiness. Readers gain a pragmatic path to faster, safer translation: case informed guidance, co design checklists, and criteria for affordability, scalability, and sustainability enable researchers and advanced students to move beyond fragmented, sequential development toward robust therapeutic systems.

• Provides a rational drug–biomaterial co design framework linking molecular properties to carrier selection and delivery strategy
• Integrates computational tools (quantum chemistry, MD, ADMET, AI/ML) with experimental validation and decision frameworks
• Addresses translational realities—toxicity, immunogenicity, regulatory pathways, manufacturing, cost, and sustainability